We are actively investing in advanced treatment platforms like Chimeric Antigen Receptor T (CAR-T) cell therapy, with efforts underway to build end-to-end capabilities in India supported by our licensing partners. Our wholly owned subsidiary, Aurigene Oncology Limited, is focused on discovering and advancing potentially best-in-class therapies for cancer and inflammatory diseases.\n\nWhile our own pipeline is in the early stages of development, we remain focused on its long-term potential to address unmet needs. In parallel, we are accelerating access to innovative products through partnerships, especially in underserved therapeutic areas and/or markets. These efforts include voluntary licensing agreements for breakthrough treatments such as Lenacapavir. Through these initiatives, we aim to make the promise of innovation a reality for patients who need it most.

In September 2022, we launched Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules approved by U. S. Food and Drug Administration (USFDA). With this volume-limited launch, we became eligible for first-to-market, 180 days of generic drug exclusivity for Dr. Reddy’s Lenalidomide Capsules in 2.5 mg and 20 mg strengths.
Our growth in North America in FY’24 was largely on account of increased volumes in the base business, including Lenalidomide as well as revenues from new products launched in FY2024. With patients at our core, in 2023 December we entered into an exclusive collaboration with Coya Therapeutics, Inc. for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS). Read more about this here. We acquired a leading women’s health and dietary supplements portfolio, MenoLabs®. We collaborated with Mark Cuban Cost Plus Drug Company, aimed at increasing access to essential medications for Wilson disease patients. We launched 20 new products, including Treprostinil Injection, Regadenoson Injection in the U.S. as well as products acquired from Mayne Pharma and filed 17 new Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (USFDA).
For selected drugs in our portfolio, we offer patient support services. We also partner with specialty pharmacies to unlock the potential of our complex and injectable generics in the growing specialty drug segment. One of the most recent ones being patient support services for Dr. Reddy’s Sapropterin Dihydrochloride. The services included a patient hub, co-pay assistance, benefits/reimbursement liaison, and nutrition and nursing support.
In addition, we have also launched our own digital marketplace for the institutional segment, DrReddysDirect.com. 

We have been present in the North American region, comprising the USA and Canada, since the mid-1990s. It is our biggest business, with revenue in FY’22 touching a historical milestone of $1 billion, and the revenue for FY’24 closing at approximately $1.6 billion. Our portfolio covers over 230 products across the retail, institutional, and over-the-counter (OTC) segments.\n\nOur pipeline includes several first-to-market drugs and complex products across drug-device combinations, peptides, and long-acting injectables.

We currently serve patients in over 14 European countries with our portfolio of generic and biosimilar medicines and OTC products across various therapeutic categories.

As healthcare challenges rise globally, we remain committed to increasing access to affordable medicines and developing products to serve unmet needs. Our generic medications are identical to approved brand-name drugs but are often available at a fraction of the cost — providing essential savings to healthcare systems and patients.

While we continue accelerating access in Europe, we have expanded our reach for consumer healthcare products by launching the anti-hay fever medicine Histallay® as an OTC product, making it available to patients faster. Our bevacizumab biosimilar received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Another essential addition to our portfolio is the drug-free migraine management wearable, Nerivio®, currently available in Germany, Spain, and the UK.

In addition to Dr. Reddy’s Laboratories, we operate through our German subsidiaries betapharm and Nimbus Health GmbH (Nimbus Health). While betapharm is a trusted brand for generics and OTC medicines, Nimbus Health is a licensed pharmaceutical wholesaler focused on medical cannabis. Medical cannabis is increasingly used to address and treat unmet medical needs, particularly in pain management and central nervous system (CNS) disorders. As more European countries adopt the usage of medical cannabis, Nimbus Health will expand into additional geographies.

As part of our growth strategy for Europe, we will continue to explore both organic and inorganic opportunities. A recent example is our signed definitive agreement with Haleon plc, a leading consumer healthcare company, to acquire shares of Northstar Switzerland SARL — a Haleon group company — and take over Haleon’s global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category outside of the United States.

This portfolio includes Nicotinell, a global leader in the NRT category with a strong presence in over 30 countries across Europe, Asia (including Japan), and Latin America. It also includes local market-leading brand names such as Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The proposed acquisition covers all formats — including lozenge, patch, gum, and pipeline products — across all applicable global markets outside of the U.S.

At Dr. Reddy’s, we focus on making everyday wellness more accessible. Our consumer health products support needs across nutrition, hydration, allergy relief, pain, and women’s health.
Our portfolio includes trusted names like Rebalanz, Celevida, Antoxid, Kidrich D3, and Becozinc. These are now part of a joint venture with Nestlé Health Science to bring high-quality nutritional solutions to India.\n\nWe also offer a global nicotine replacement therapy (NRT) range, including Nicotinell, Nicabate, Thrive, and Habitrol. These are available in over 30 countries.
In the United States, we have well-known brands like Habitrol, Doan’s, Premama, and MenoLabs. In India, we serve daily health needs in hydration, cough and cold, and skin care. We are also growing in markets like the UK, Russia, South Africa, Asia, and Latin America\n\nWe continue to invest in brand building, digital tools, and e-commerce. Our goal is to meet real needs with safe, effective, and affordable products.

India is a strong focus area for us. In the last few years, India business has contributed an increased share to our overall business. Our market rank was 10th as per Moving quarterly total (MQT) and 11th as per Moving Annual Total (MAT) in terms of sales value in March 2024. We aspire to break into the top 5 in India. Building and maintaining big brands, strong product launch momentum, dedicated R&D for differentiated products, strengthening our position in key and high-growth segments, and strategic inorganic opportunities will be key pillars to achieving this aspiration. We continue to drive our productivity enhancement in the field, tapping into digital and omni-channel marketing and other mediums.\n\nWe have established a leading presence in therapy areas such as oncology, gastroenterology, allergy, diabetics, pain management, among others. We became the 2nd largest vaccines player in India, through an exclusive partnership with Sanofi to distribute their vaccine brands in India. We launched drug-free migraine management device, Nerivio®, our first digital therapeutic product in India. We forayed into trade generics to increase our participation in the retail pharmaceutical market. We entered into a licensing agreement with U.S.-based biopharma, Pharmazz, to market first-in-class Centhaquine (Lyfaquin®) for treatment of hypovolemic shock in India. We partnered with Bayer to distribute the second brand for heart failure management drug, Vericiguat, in India and partnered with Jiangsu Hengrui Pharmaceuticals Co. Ltd. to promote its oral breast cancer NCE, Pyrotinib, in India. We entered into an exclusive licence agreement with Wellington Zhaotai Therapies Limited to develop and commercialise a Chimeric antigen receptor - T (CAR-T) cell therapy asset, ‘WL-002’ in India. The CAR-T asset ‘DRL-1801’ was approved for clinical trial in India. We launched 13 new brands in India.\n\nWe look forward to our India business continuing to be a key growth driver for us and contributing to our goal of serving over 1.5 billion patients by 2030.

The Emerging Markets business is working to make our products available in new markets. Our focus is to improve the market share in the chosen therapy areas through growth in the existing products as well as new product launches, supported by sales and marketing excellence. Our medium-term strategy for the segment is to build a healthy portfolio pipeline, including oncology products, coupled with the expansion of biosimilars. We will continue to focus on building big brands and winning in chosen therapy areas through differentiated portfolio. We will further scale up in our major markets, which include Russia, China, Brazil, and South Africa and add new geographies by leveraging our in-house global portfolio of generics and biosimilars and seeking in-licensing opportunities. In the long term, our focus will be on introducing innovative products (sourced externally or developed in-house) to branded markets—such as Novel Assets like NCE/NBEs and Digital Therapeutics—and driving consumer innovation in OTC, Wellness, and Nutrition sectors.\n\nWe have our presence in Russia for over 30 years and it is a key market for us. IQVIA ranked us 15th in terms of sales in Russia on March 31, 2024. This was driven by improved existing business performance, launch of new products during the year along with divestment of some non-core brands. For the sixth year in a row, 6 of our leading products were voted as the ‘Product of the Year 2023’ in the popular choice category – reaffirming the trust that the people of Russia have in them.\n\nWe were among the earliest Indian pharma companies to have a business presence in China. We have a representative office that focuses on filings and approvals, and participation in procurement by Group Purchasing Organisation (GPO). Our joint venture entity (Kunshan Rotam Reddy Pharmaceutical Co. Ltd) offers a portfolio of niche and essential products, strengthening our presence in China.\n\nIn Latin America we have a strong presence in Brazil and Colombia. In just a little over seven years in Brazil, our team has established itself in the region with our diverse portfolio. Our primary focus in Brazil is oncology and institutional.\n\nRecently, we have expanded our presence in Central America across 9 countries and countries neighbouring Chile. In 2024, we inaugurated our new office and warehouse in Jamaica.\n\nWe were recognised as ‘Company of the Year – Americas’ for the second year in a row at the Global Generics & Biosimilars Awards 2023! Our teams in China, Brazil, Colombia, Malaysia and Thailand have earned the Great Place to Work certification. Our team in Russia won the HeadHunter’s Best Employer Ranking in 2023. In South Africa, we were recognised as the Top Employer 2024. These certifications are a recognition of our work culture and environment, and of the employer brand that we have created. We believe in setting up our people for success with progressive people practices, empowering them to lead from the front and equipping them with the right skills to be efficient and effective.\n\nWith the aim of reaching more and more patients around the world, we are harnessing our deep science capabilities to create a robust portfolio in the region to become the partner of choice. As the need, scope and standards of healthcare evolve, we keep track of emerging needs to contribute to patient welfare. After all, Good Health Can’t Wait.

With expertise in bacterial and mammalian cell-derived biosimilars, developed using recombinant DNA technology, we manufacture these products in dedicated facilities to ensure precision, safety, and accessibility. Our biologics portfolio includes seven biosimilar products and one novel biologic, marketed across multiple countries, supporting patients in oncology and immunology.

At Dr. Reddy’s Biologics, collaboration is key to driving progress. We engage in in-licensing, out-licensing, and co-development partnerships to accelerate breakthroughs and expand treatment options. Our work with global leaders in biopharmaceutical space strengthens our position in the industry.

Our biologics capabilities extend beyond biosimilars. From biosimilars and novel biologics to cell and gene therapy and contract development and manufacturing (CDMO), we offer comprehensive biologics solutions. Supported by state-of-the-art research and manufacturing facilities, including EMA approved facility, we maintain high standards to ensure reliability in every aspect of development and production.

With over 1 million patients treated globally, we continue to focus on responsible development and trusted partnerships. Our proposed biosimilars, currently under review by the US FDA, represents our ongoing efforts to improve biologics accessibility. Additionally, our biologics portfolio includes partnerships to develop and bring innovative therapeutic solutions designed to support critical patient needs.

Dr. Reddy’s Biologics remains dedicated to expanding access to advanced therapies through scientific progress, responsible development, and reliable manufacturing.